title: Civil society perspectives on negative biomedical HIV prevention trial results and implications for future trials.
abstract: Community engagement is crucial to ongoing development and testing of sorely needed new biomedical HIV prevention technologies. Yet, negative trial results raise significant challenges for community engagement in HIV prevention trials, including the early termination of the Cellulose Sulfate microbicide trial and two Phase IIb HIV vaccine trials (STEP and Phambili). The present study aimed to explore the perspectives and experiences of civil society organization (CSO) representatives regarding negative HIV prevention trial results and perceived implications for future trials. We conducted in-depth interviews with 14 respondents from a broad range of South African and international CSOs, and analyzed data using thematic analysis. CSO representatives reported disappointment in response to negative trial results, but acknowledged such outcomes as inherent to clinical research. Respondents indicated that in theory negative trial results seem likely to impact on willingness to participate in future trials, but that in practice people in South Africa have continued to volunteer. Negative trial results were described as having contributed to improving ethical standards, and to a re-evaluation of the scientific agenda. Such negative results were identified as potentially impacting on funding for trials and engagement activities. Our findings indicate that trial closures may be used constructively to support opportunities for reflection and renewed vigilance in strategies for stakeholder engagement, communicating trial outcomes, and building research literacy among communities; however, these strategies require sustained resources for community engagement and capacity-building.
authors.affiliation: HIV AIDS Vaccines Ethics Group, School of Psychology, University of KwaZulu-Natal, Pietermaritzburg, KwaZulu-Natal, South Africa.
authors.forename: Zaynab
authors.initials: Z
authors.lastname: Essack
authors.forename: Jennifer
authors.initials: J
authors.lastname: Koen
authors.forename: Catherine
authors.initials: C
authors.lastname: Slack
authors.forename: Graham
authors.initials: G
authors.lastname: Lindegger
authors.forename: Peter A
authors.initials: PA
authors.lastname: Newman
mesh_terms: D016915:AIDS Vaccines; D035843:Biomedical Research; D003140:Communicable Disease Control / Q000458:organization & administration* / Q000639:trends; D057239:Early Termination of Clinical Trials / Q000706:statistics & numerical data*; D005260:Female; D015658:HIV Infections / Q000517:prevention & control*; D006801:Humans; D008297:Male; D009313:National Health Programs / Q000458:organization & administration / Q000639:trends; D010358:Patient Participation; D055818:Public-Private Sector Partnerships / Q000458:organization & administration* / Q000639:trends; D012107:Research Design; D012109:Research Support as Topic / Q000458:organization & administration*; D013019:South Africa
chemical_list: D016915:AIDS Vaccines